Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Daiichi Sankyo Ltd ADR (DSNKY)

Daiichi Sankyo Ltd ADR (DSNKY)
23.3800 +0.1000 (+0.43%) 12:49 ET [OTC US]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
23.2200
Day High
23.7700
Open 23.6050
Previous Close 23.2800 23.2800
Volume 10,300 10,300
Avg Vol 380,144 380,144
Stochastic %K 50.11% 50.11%
Weighted Alpha -32.53 -32.53
5-Day Change +0.8100 (+3.58%) +0.8100 (+3.58%)
52-Week Range 20.9200 - 42.4800 20.9200 - 42.4800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 44,425,740
  • Shares Outstanding, K 1,908,322
  • Annual Sales, $ 11,052 M
  • Annual Income, $ 1,385 M
  • EBIT $ 595 M
  • EBITDA $ 1,872 M
  • 60-Month Beta N/A
  • Price/Sales 3.75
  • Price/Cash Flow N/A
  • Price/Book 4.04
  • Price/Earnings ttm 26.57
  • Earnings Per Share ttm 0.86
  • Most Recent Earnings $0.22 on 01/31/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.13
  • Growth Rate Est. (year over year) +768,361.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.9200 +11.90%
on 04/11/25
Period Open: 24.8200
25.5800 -8.48%
on 03/25/25
-1.4100 (-5.68%)
since 03/21/25
3-Month
20.9200 +11.90%
on 04/11/25
Period Open: 28.4400
29.6800 -21.13%
on 01/30/25
-5.0300 (-17.69%)
since 01/23/25
52-Week
20.9200 +11.90%
on 04/11/25
Period Open: 30.2900
42.4800 -44.89%
on 08/29/24
-6.8800 (-22.71%)
since 04/23/24

Most Recent Stories

More News
1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer...

AZN : 68.69 (+1.21%)
MS : 113.25 (+2.60%)
DSNKY : 23.3800 (+0.43%)
PFE : 22.39 (-0.62%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

AZN : 68.69 (+1.21%)
GMAB : 20.12 (-0.74%)
NVO : 61.33 (+2.37%)
JNJ : 155.47 (-1.45%)
MRK : 78.86 (-0.14%)
DSNKY : 23.3800 (+0.43%)
LLY : 826.16 (-0.17%)
ABBV : 176.05 (+1.31%)
RHHBY : 39.0100 (+0.08%)
PFE : 22.39 (-0.62%)
300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Rates

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

ONCY : 0.5743 (-4.00%)
AZN : 68.69 (+1.21%)
ARAY : 1.5350 (+0.99%)
DSNKY : 23.3800 (+0.43%)
GILD : 105.67 (+0.15%)
ONC.TO : 0.80 (-4.76%)
Investing in Hope: Biotech Innovations Targeting Increased Breast Cancer Rates in 2023

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

ONCY : 0.5743 (-4.00%)
AZN : 68.69 (+1.21%)
ARAY : 1.5350 (+0.99%)
DSNKY : 23.3800 (+0.43%)
GILD : 105.67 (+0.15%)
ONC.TO : 0.80 (-4.76%)
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?

In due time, its new partnership with Daiichi Sankyo could be massive.

MRK : 78.86 (-0.14%)
DSNKY : 23.3800 (+0.43%)
Is Gilead Sciences a Good Stock to Buy Now?

Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.

AZN : 68.69 (+1.21%)
DSNKY : 23.3800 (+0.43%)
GILD : 105.67 (+0.15%)
PFE : 22.39 (-0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Daiichi Sankyo Company Limited manufactures and sells pharmaceutical products principally in Japan, North America, Europe and internationally. Daiichi Sankyo Company Limited is based in Tokyo, Japan.

See More

Key Turning Points

3rd Resistance Point 24.3600
2nd Resistance Point 23.8600
1st Resistance Point 23.5700
Last Price 23.3800
1st Support Level 22.7800
2nd Support Level 22.2800
3rd Support Level 21.9900

See More

52-Week High 42.4800
Fibonacci 61.8% 34.2441
Fibonacci 50% 31.7000
Fibonacci 38.2% 29.1559
Last Price 23.3800
52-Week Low 20.9200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro